No Data
Heron Therapeutics Down Over 19%, On Pace for Largest Percent Decrease Since May 2023 -- Data Talk
Heron Therapeutics Inc.(HRTX) is currently at $2.79, down $0.68 or 19.62% --Would be lowest close since May 10, 2024, when it closed at $2.77 --On pace for largest percent decrease since May 12, 202
Heron Therapeutics Shares Are Trading Lower. The FDA Acknowledged the Receipt of the Company's Prior Approval Supplement Application for ZYNRELEF.
Heron Therapeutics Shares Are Trading Lower. The FDA Acknowledged the Receipt of the Company's Prior Approval Supplement Application for ZYNRELEF.
Heron Therapeutics' ZYNRELEF Review Date Set by FDA
Express News | Heron Therapeutics Inc - U.S. Food and Drug Administration ("FDA") Assigned a Prescription Drug User Fee Act ("Pdufa") Goal Date of September 23, 2024
Express News | Heron Therapeutics Announces Acceptance of the Prior Approval Supplement Application for Zynrelef® Vial Access Needle ("Van")
With 55% Ownership of the Shares, Heron Therapeutics, Inc. (NASDAQ:HRTX) Is Heavily Dominated by Institutional Owners